



## ***Press Release***

# **PathoQuest, a Kurma Partners portfolio company, announces a definitive agreement to be acquired by Charles River Laboratories**

***PathoQuest was built and supported by Kurma Partners and the Pasteur Institute and  
based on the groundbreaking work of Prof. Marc Eloit***

**Paris, France, January 12, 2026** – PathoQuest, a Kurma Partners portfolio company, pioneer and global leader in Next Generation Sequencing (NGS)-based biosafety testing, announces today that it has entered into a definitive agreement to be acquired by Charles River Laboratories, a leading global provider of products and services that advance biopharmaceutical research, development, and manufacturing.

Headquartered in Paris, France, with a U.S. site in Wayne, Pennsylvania, PathoQuest supports pharmaceutical, biotech, and CDMO partners worldwide. Its proprietary iDTECT® platform delivers state-of-the-art viral safety and genetic characterization testing designed to meet the rapidly evolving needs of advanced biologic modalities, including cell and gene therapies, and vaccines.

This milestone marks a powerful new chapter for PathoQuest, reinforcing its mission to transform biosafety testing through faster, animal-free, and GMP-compliant genomic solutions. By joining forces with Charles River Laboratories, PathoQuest's innovative technologies will benefit from a truly global footprint, accelerating adoption across the full biopharmaceutical lifecycle.

*“This transaction represents a defining moment in PathoQuest’s journey,” said **Jean-François Brepson, CEO of PathoQuest**. “Thanks to the trust and long-term support of our investors, we have built a world-class NGS platform that is reshaping biosafety testing. Joining Charles River enables us to expand our global impact and provide our faster, animal-free, GMP-compliant solutions to even more innovators worldwide.”*

*“Pathoquest is another illustration of the strong capabilities of Kurma Partners to identify groundbreaking science from European universities and to launch successful companies with strong industry and medical needs and high impact”, said **Thierry Laugel, partner at Kurma Partners**.*

---

## **About Kurma Partners**

Founded in 2009 in Paris, Kurma Partners has become a key player in Europe, financing innovation to build the healthcare industry of tomorrow. Kurma invests from company formation to growth capital, across the spectrum of healthcare through specialized franchises. The franchises continue to expand with successive funds focused on biotechnology (Biofunds I, II, III, IV - the latter has a target of €250 million), digital health & diagnostics (Kurma Diagnostics and Kurma Diagnostics 2) and more recently, growth opportunities (Kurma Growth Opportunity Fund). The Kurma teams comprise a total of 25 people, including 10 partners, and are based in two offices, in Paris and Munich. They are heavily involved in the European ecosystem and have built up a strong network of international connections with prestigious research institutes, hospitals, entrepreneurs, industrial players, and fellow investors.

Kurma Partners is part of the Eurazeo group.

For further information: [www.kurmapartners.com](http://www.kurmapartners.com)

## **About PathoQuest**

With more than 20 peer-reviewed publications on NGS applications, PathoQuest is a recognized leader in GMP-compliant Next Generation Sequencing-based biosafety testing. The company provides biopharmaceutical developers with a game-changing genomic approach to ensuring the safety of biologics, including cell and gene therapies, vaccines, and recombinant proteins—helping reduce development timelines and accelerate patient access to innovative therapies. Headquartered in Paris, France, with a U.S. site in Wayne, Pennsylvania, PathoQuest has partnered with more than 100 leading biopharmaceutical companies worldwide.

Learn more at [www.pathoquest.com](http://www.pathoquest.com).

---

## **Kurma press contact**

### **Agence Maarc**

Nicolas Daniels / +33 (0)6 63 66 59 22 / [nicolas.daniels@maarc.fr](mailto:nicolas.daniels@maarc.fr)